Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. Smoking in combination with oral-contraceptive use has been shown to contribute in the incidence of disease between oral-contraceptive users and nonusers. The Throughout this labeling, epidemiological studies reported are of two types: carried out in patients who used oral contraceptives with higher formulations

In the randomized trials of the noted in the above, smoking increases the risk of heart attacks and strokes and subsequent measures should be undertaken immediately. The administration of oral contraceptives to induce withdrawal bleeding should not be started more than 5 days after delivery to prevent hemorrhage in a patient with placental retention. Oral-contraceptive use should be considered at the time of the first missed period. Oral-contraceptive use should be Pregnancy to treat threatened or habitual abortion. Adapart from H.W. Ory, Family Planning Perspectives, 57-63, 1983.

The administration of oral contraceptives to induce withdrawal bleeding should not be started more than 5 days after delivery to prevent hemorrhage in a patient with placental retention. Oral-contraceptive use should be considered at the time of the first missed period. Oral-contraceptive use should be

**Table II.**

<table>
<thead>
<tr>
<th>Method</th>
<th>5 Non-Hispanic</th>
<th>5 Hispanic</th>
<th>10 Non-Hispanic</th>
<th>10 Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral contraceptives</td>
<td>2.5</td>
<td>1.6</td>
<td>1.6</td>
<td>1.7</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>2.9</td>
<td>3.6</td>
<td>1.4</td>
<td>1.5</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>3.1</td>
<td>3.5</td>
<td>3.2</td>
<td>3.6</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>3.3</td>
<td>3.7</td>
<td>3.4</td>
<td>3.6</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>3.5</td>
<td>3.8</td>
<td>3.5</td>
<td>3.8</td>
</tr>
</tbody>
</table>

The contraceptive effects on risk factors have been associated with an increased risk of heart disease. Changes in appetite.

Migraine.

Edema.

Temporary infertility after discontinuation of treatment.

Nausea.

Arterial thromboembolism.

An increased risk of the following serious adverse reactions has been associated with

In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These tumors, which may comprise the liver, may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancers in two studies in

In the comparison of two studies of the noted in the above, smoking increases the risk of heart attacks and strokes and subsequent measures should be undertaken immediately. The administration of oral contraceptives to induce withdrawal bleeding should not be started more than 5 days after delivery to prevent hemorrhage in a patient with placental retention. Oral-contraceptive use should be considered at the time of the first missed period. Oral-contraceptive use should be

**Table II.**

<table>
<thead>
<tr>
<th>Method</th>
<th>5 Non-Hispanic</th>
<th>5 Hispanic</th>
<th>10 Non-Hispanic</th>
<th>10 Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral contraceptives</td>
<td>2.5</td>
<td>1.6</td>
<td>1.6</td>
<td>1.7</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>2.9</td>
<td>3.6</td>
<td>1.4</td>
<td>1.5</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>3.1</td>
<td>3.5</td>
<td>3.2</td>
<td>3.6</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>3.3</td>
<td>3.7</td>
<td>3.4</td>
<td>3.6</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>3.5</td>
<td>3.8</td>
<td>3.5</td>
<td>3.8</td>
</tr>
</tbody>
</table>

The contraceptive effects on risk factors have been associated with an increased risk of heart disease. Changes in appetite.

Migraine.

Edema.

Temporary infertility after discontinuation of treatment.

Nausea.

Arterial thromboembolism.

An increased risk of the following serious adverse reactions has been associated with

In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These tumors, which may comprise the liver, may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancers in two studies in

In the comparison of two studies of the noted in the above, smoking increases the risk of heart attacks and strokes and subsequent measures should be undertaken immediately. The administration of oral contraceptives to induce withdrawal bleeding should not be started more than 5 days after delivery to prevent hemorrhage in a patient with placental retention. Oral-contraceptive use should be considered at the time of the first missed period. Oral-contraceptive use should be
1. Take the first "active" beige pill of the first pack during the first 24 hours of your period. This is called the "1-2-3" method. If you start the pack the 4th day of your period, start the "3-week" pack on day 4. Take beige, white or light-yellow "active" pills in a row for 21 days. You may take 2 pills in 1 day. Do not take extra pills for omitted pills.

2. Missed Pills:
- If you miss 1 pill, take it as soon as you remember. Then take the next pill on schedule. If you miss 2 pills, take them right away and continue taking 1 pill a day. If you miss 3 or more pills, omit the missed pills. Continue taking 1 pill a day. If you are not a Day 1 Starter, take 1 pill daily from the day you start your "active" pack. Do not skip days if you are spotting or bleeding between monthly periods or feel an unusual amount of breast tenderness.

3. You MAY BECOME PREGNANT if you have sex in the 7 days before you start your new pack. You MUST use another birth-control method (such as condoms, foam, or sponge) as a back-up for those 7 days.

4. BE SURE YOU HAVE READY AT ALL TIMES:
- DAY 1 STARTERS: Take 1 pill daily from the day you start your "active" pack.
- SUNDAY START: Take the first "active" beige pill of the first pack during the 1st 24 hours of your period. Take beige, white or light-yellow "active" pills in a row for 21 days.

5. Other side effects may include:
- Change in appetite.
- Headache.
- Nervousness.
- Breast tenderness.
- Mood changes.
- Bruising.
- Rash.
- Blood in the urine.
- Irregular vaginal bleeding or spotting may occur while you are taking the pills.

6. Drug interactions:
- Rifampin may make the pill less effective.
- Antacids, antibiotics, and hormone drugs may lower pill effectiveness.
- Birth-control pill effectiveness may be decreased if taken with other hormone drugs.
- Miscellaneous (especially medicines that lower the body's ability to form blood clots) may reduce effectiveness.
- If you are pregnant, your birth-control pill will not work. Use alternate birth-control measures.

7. Pregnancy after stopping the pill:
- Irregular vaginal bleeding or spotting may occur while you are taking the pills.
- Other side effects may include:
- Change in appetite.
- Headache.
- Nervousness.
- Breast tenderness.
- Mood changes.
- Bruising.
- Rash.
- Blood in the urine.
- Irregular vaginal bleeding or spotting may occur while you are taking the pills.

8. The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on the risk of death. This would be a very rare event in the absence of smoking.
NOM DU PRODUIT / PRODUCT NAME: MYZILRA PI 3'S
NUMÉRO DU PRODUIT / PRODUCT NUMBER: 2000004319
N° CODE À BARRES / BARCODE NO.: 4319

SPÉCIFICATIONS

TYPE DE PAPIER / PAPER TYPE: OFFSET
POIDS DU PAPIER / PAPER WEIGHT: 30 LB, 60 M
DIMENSIONS (MM): À PLAT / FLAT: 473 x 299
PLIÉ / FOLDED: 53 x 38
POINTS DE COLLE / GLUE SPOTS: 2
FEUILLET PLIÉ / FOLDED LEAFLET: ANGLAIS / ENGLISH VISIBLE
FRANÇAIS / FRENCH VISIBLE
AUTRE / OTHER VISIBLE

APPROBATION / APPROVAL

ÉPREUVES DE L'IMPRIMEUR / VENDOR'S PROOF

APPRO.: _________________________  SIGNATURE: ____________________________________
APP.: _________________________  DATE: __________________
APP.: _________________________  DATE: __________________
APP.: _________________________  DATE: __________________

COULEUR(S) / COLOR(S):
#1
F Noir/BLACK

APPRO.: SIGNATURE: _________________________

DATE: ____________________